News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Lynn McRoy

Articles by Lynn McRoy

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Doris Makari,Rachel M. Layman,Hope S. Rugo, MD

August 20th 2024

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M. Layman,Hope S. Rugo, MD

April 28th 2023

49 Financial Toxicity Among Patients With Breast Cancer During the COVID-19 Pandemic

ByYan Wu,Xianchen Liu,Martine C. Maculaitis,Benjamin Li,Alexa Berk,Angelina Massa,Marisa C. Weiss,Lynn McRoy

April 26th 2023

18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19

ByMartine C. Maculaitis,Xianchen Liu,Alexandra Berk,Angelina Massa,Marisa C. Weiss,Samantha M. Kurosky,Benjamin Li,Lynn McRoy

May 6th 2022

Latest Updated Articles

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
Published: April 28th 2023 | Updated:

Trending on CancerNetwork

177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC

Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC

H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice

FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

© 2025 MJH Life Sciences^®

All rights reserved.